Business
IceCure Medical Reports 2024 Financial Results: 42% Growth in ProSense® Cryoablation Sales in North America
IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today reported financial results as of and for the twelve months ended December 31, 2024.
About this update from Icecure Medical Ltd.
[{"type":"text","content":"Expecting FDA decision on marketing authorization for early-stage low risk breast cancer with endocrine therapy","length":111,"tagName":"p","attribs":{}},{"type":"text","content":"Positive ProSense® results were reported through 33 peer-reviewed journals and medical conferences during 2024","length":115,"tagName":"p","attribs":{}},{"type":"text","content":"Conference call to be held today at 10:00 am Eastern Time","length":57,"tagName":"p","attribs":{}},{"type":"text","content":"CAESAREA, Israel, March 27, 2025 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today reported financial results as of and for the twelve months ended December 31, 2024.","length":392,"tagName":"p"},{"type":"image","alt":"IceCure Medical Logo","displaySize":"","headline":null,"caption":"IceCure Medical Logo","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":200,"url":"https://media.zenfs.com/en/prnewswire.com/b733b9648e0c5c7b36e9d5bf48d042cc"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/2XUcwzAVdZCf5Oz2LQaIEw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTM1MztjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/b733b9648e0c5c7b36e9d5bf48d042cc","width":400,"height":200}}},{"type":"text","content":"IceCure continues to engage with the U.S. Food and Drug Administration ("FDA") regarding its De Novo marketing authorization request for ProSense® in early-stage low risk breast cancer with endocrine therapy. Should ProSense® receive marketing authorization in this indication, ProSense® would become a first-in-class minimally invasive alternative to standard of care lumpectomy.","length":400,"tagName":"p"},{"type":"text","content":""The sales momentum we have experienced in 2024 for ProSense® in North America, as well as in Europe and Japan, are encouraging signs that a positive marketing clearance outcome in the U.S. may lead to a higher adoption of ProSense®. Early interest in the U.S. for breast cancer cryoablation is evident following the favorable decision of the FDA Medical Device Advisory Panel ("Advisory Panel") in November 2024," stated IceCure Medical&#...